GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Loans Receivable

Bio-Techne (BSP:T1CH34) Loans Receivable : R$0 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Loans Receivable?

Bio-Techne's Loans Receivable for the quarter that ended in Mar. 2024 was R$0 Mil.


Bio-Techne Loans Receivable Historical Data

The historical data trend for Bio-Techne's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Loans Receivable Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bio-Techne Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Bio-Techne Loans Receivable Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (BSP:T1CH34) Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (BSP:T1CH34) Headlines

No Headlines